![Grant Yonehiro](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Grant Yonehiro
Directeur des opérations chez
BOLT BIOTHERAPEUTICS, INC.
Fortune : 2 336 $ au 31/05/2026
Profil
Grant Yonehiro is Chief Operating Officer at Bolt Biotherapeutics, Inc. since 2024.
Formerly, Mr. Yonehiro was President & Chief Executive Officer at Perseid Therapeutics LLC from 2009 to 2013, Vice President-Commercial Operations at GenVec, Inc. from 1997 to 2003, Chief Business Officer at Maxygen, Inc. from 2003 to 2009, Chief Commercial Officer at Vium, Inc. in 2016, and Chief Business Officer at Phenomebio, Inc. from 2013 to 2016.
Education includes an MBA from the University of California, Berkeley, an undergraduate degree from the University of Minnesota, and an MBA from Haas School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/03/2026 | 445 ( 0,02% ) | 2 336 $ | 31/05/2026 |
Postes actifs de Grant Yonehiro
| Sociétés | Poste | Début |
|---|---|---|
| BOLT BIOTHERAPEUTICS, INC. | Directeur des opérations | 15/05/2024 |
Anciens postes connus de Grant Yonehiro
| Sociétés | Poste | Fin |
|---|---|---|
Vium, Inc.
 Vium, Inc. Information Technology ServicesTechnology Services Provides technology for preclinical drug discovery services | Corporate Officer/Principal | 01/11/2016 |
Berkeley Lights, Inc.
 Berkeley Lights, Inc. Packaged SoftwareTechnology Services Develops and commercializes platforms for bio-pharmaceutical, genomic and cellular therapy applications | Corporate Officer/Principal | 01/01/2016 |
Perseid Therapeutics LLC
 Perseid Therapeutics LLC Pharmaceuticals: MajorHealth Technology Develops protein drugs | Directeur Général | 01/09/2013 |
Maxygen, Inc.
 Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Develops directed molecular evolution technology | Corporate Officer/Principal | 01/09/2009 |
| GENVEC INC | Corporate Officer/Principal | 01/04/2003 |
Formation de Grant Yonehiro
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
28
Relations au 1er degré
9
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
GenVec, Inc.
 GenVec, Inc. Pharmaceuticals: MajorHealth Technology Develops bio-pharmaceutical products | Health Technology |
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Develops directed molecular evolution technology | Commercial Services |
Vium, Inc.
Vium, Inc. Information Technology ServicesTechnology Services Provides technology for preclinical drug discovery services | Technology Services |
University of California, Berkeley
 University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Minnesota
 University of Minnesota Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Haas School of Business
 Haas School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Perseid Therapeutics LLC
Perseid Therapeutics LLC Pharmaceuticals: MajorHealth Technology Develops protein drugs | Health Technology |
Bolt Biotherapeutics, Inc.
 Bolt Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage immuno-oncology company | Health Technology |
Berkeley Lights, Inc.
Berkeley Lights, Inc. Packaged SoftwareTechnology Services Develops and commercializes platforms for bio-pharmaceutical, genomic and cellular therapy applications | Technology Services |
